PMID- 21134821
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20171116
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 97
IP  - 12
DP  - 2010 Dec
TI  - [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
PG  - 1429-40
LID - 10.1684/bdc.2010.1224 [doi]
AB  - HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene 
      amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or 
      gastro-oesophageal junction (GOJ) cancers. Most studies have shown that 
      HER2-overexpressing gastric cancers were worse prognosis. Trastuzumab is a 
      humanized monoclonal antibody directed against HER2 with known efficacy in 
      patients with HER2+ early or metastatic breast cancer. The international 
      randomized trial ToGA study showed the superiority of the combination of 
      trastuzumab with chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) 
      plus cisplatin (FP) every three weeks compared with chemotherapy alone in terms 
      of overall survival : 13.8 versus 11.1 months (HR: 0.74, 95% CI: 0.60-0.91, P = 
      0.0046) in HER2+ advanced gastric cancers. The benefit was even greater in the 
      subgroup with HER2 overexpression (16% of the screened population) as defined by 
      IHC3+ or IHC2+ confirmed by positive ISH test. Trastuzumab plus FP chemotherapy 
      has become the standard treatment for patients with HER2+ non-pretreated 
      metastatic adenocarcinoma of the stomach or GOJ cancer. All these cancers should 
      be tested for HER2 on paraffin block resection or biopsy specimens of the primary 
      tumour or metastases. Endoscopic gastric biopsies should be multiple. The IHC 
      should be the initial test. The standardized immunohistochemical scoring system 
      differs from that recommended for breast cancer given the heterogeneity of HER2 
      expression and the frequency of incomplete membranous staining in gastric 
      cancers. Equivocal IHC2+ tumours should be tested by ISH with two tools: 
      fluorescence in situ hybridization (FISH) or bright field in situ hybridization 
      (SISH). The perspectives are the assessment of trastuzumab in the perioperative 
      and adjuvant setting, the development of novel anti-HER2 drugs and research into 
      mechanisms of resistance and predictive molecular markers.
FAU - Bouche, O
AU  - Bouche O
AD  - Service d'hepatogastroenterologie et de cancerologie digestive, CHU de Reims, 
      Hopital Robert-Debre, avenue du General-Koenig, 51092 Reims cedex, France. 
      obouche@chu-reims.fr
FAU - Penault-Llorca, F
AU  - Penault-Llorca F
LA  - fre
PT  - Journal Article
PT  - Review
TT  - HER2 et cancer de l'estomac : une nouvelle cible therapeutique 
      pour le trastuzumab.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Capecitabine
MH  - Cisplatin/administration & dosage
MH  - Contraindications
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - *Esophagogastric Junction
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization/methods
MH  - Paraffin Embedding
MH  - Randomized Controlled Trials as Topic
MH  - Receptor, ErbB-2/*analysis/antagonists & inhibitors
MH  - Stomach Neoplasms/chemistry/*drug therapy
MH  - Trastuzumab
EDAT- 2010/12/08 06:00
MHDA- 2011/02/04 06:00
CRDT- 2010/12/08 06:00
PHST- 2010/12/08 06:00 [entrez]
PHST- 2010/12/08 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
AID - S0007-4551(15)30729-3 [pii]
AID - 10.1684/bdc.2010.1224 [doi]
PST - ppublish
SO  - Bull Cancer. 2010 Dec;97(12):1429-40. doi: 10.1684/bdc.2010.1224.